ZA200301673B - Cathartic composition. - Google Patents

Cathartic composition.

Info

Publication number
ZA200301673B
ZA200301673B ZA200301673A ZA200301673A ZA200301673B ZA 200301673 B ZA200301673 B ZA 200301673B ZA 200301673 A ZA200301673 A ZA 200301673A ZA 200301673 A ZA200301673 A ZA 200301673A ZA 200301673 B ZA200301673 B ZA 200301673B
Authority
ZA
South Africa
Prior art keywords
cathartic composition
cathartic
composition
Prior art date
Application number
ZA200301673A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200301673(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of ZA200301673B publication Critical patent/ZA200301673B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
ZA200301673A 2000-09-05 2003-02-28 Cathartic composition. ZA200301673B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition

Publications (1)

Publication Number Publication Date
ZA200301673B true ZA200301673B (en) 2003-11-26

Family

ID=24630250

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200301673A ZA200301673B (en) 2000-09-05 2003-02-28 Cathartic composition.

Country Status (25)

Country Link
US (7) US6414016B1 (ru)
EP (2) EP1857105B1 (ru)
JP (3) JP2004508327A (ru)
KR (2) KR100918223B1 (ru)
CN (1) CN100335049C (ru)
AR (2) AR030609A1 (ru)
AT (1) ATE476975T1 (ru)
AU (2) AU2001282615B2 (ru)
BR (1) BRPI0114042B8 (ru)
CA (1) CA2419741C (ru)
CZ (1) CZ304740B6 (ru)
DE (2) DE60142810D1 (ru)
DK (2) DK1857105T3 (ru)
ES (2) ES2347697T3 (ru)
HU (1) HU229319B1 (ru)
IL (2) IL154534A0 (ru)
MX (1) MXPA03001959A (ru)
NL (1) NL300757I2 (ru)
NO (1) NO332701B1 (ru)
NZ (1) NZ524401A (ru)
PT (2) PT1857105E (ru)
RU (1) RU2694361C3 (ru)
TW (1) TWI305147B (ru)
WO (1) WO2002020007A1 (ru)
ZA (1) ZA200301673B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4332316B2 (ja) 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
EP1562604B1 (en) * 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
MXPA05006981A (es) * 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
US8337891B2 (en) 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
EP2332545A1 (en) * 2005-01-27 2011-06-15 Sucampo AG Composition for treating central nervous system disorders
NZ561414A (en) 2005-03-04 2010-10-29 Sucampo Ag Method and composition for treating peripheral vascular diseases
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
WO2006109881A1 (en) * 2005-04-12 2006-10-19 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
WO2007086541A2 (en) * 2006-01-24 2007-08-02 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
CN101379051B (zh) * 2006-02-07 2014-05-28 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
US8372425B2 (en) * 2008-10-31 2013-02-12 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ES2657938T3 (es) 2008-12-31 2018-03-07 Ardelyx, Inc. Compuestos y métodos para inhibir el antipuerto mediado por NHE en el tratamiento de trastornos asociados a la retención de líquidos o a la sobrecarga de sales y trastornos del tracto gastrointestinal
WO2010083597A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
CN104958298A (zh) * 2009-09-18 2015-10-07 阿得罗公司 阿片样受体拮抗剂用于胃肠道疾病的用途
WO2011054087A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
EP2516412A4 (en) * 2009-12-18 2013-05-29 Apotex Pharmachem Inc PROCESS FOR CLEANING LUBIPROSTON
EP2536705A4 (en) 2010-01-28 2013-08-07 Apotex Pharmachem Inc POLYMORPHIC FORMS OF LUBIPROSTON
CN104902930A (zh) 2012-08-21 2015-09-09 阿德利克斯公司 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
ES2735992T3 (es) 2013-04-12 2019-12-23 Ardelyx Inc Compuestos de unión a NHE3 y procedimientos para inhibir el transporte de fosfatos
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
AR105029A1 (es) * 2015-06-19 2017-08-30 Sucampo Ag Composición farmacéutica que comprende derivado de ácido graso
WO2018065826A1 (en) 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
EP3565808A1 (en) 2017-01-09 2019-11-13 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
CN110494721B (zh) * 2017-04-20 2022-06-24 株式会社岛津制作所 分光光度计
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (ru) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ATE78465T1 (de) * 1987-10-02 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
CN1160079C (zh) * 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
JP4332316B2 (ja) * 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
AU2001287580A1 (en) * 2000-07-14 2002-01-30 Henkel Kommanditgesellschaft Auf Aktien Hollow bodies with compartments
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Also Published As

Publication number Publication date
US8071613B2 (en) 2011-12-06
NL300757I1 (ru) 2015-12-29
US20120237598A1 (en) 2012-09-20
AU2001282615B2 (en) 2006-06-22
EP1315485A1 (en) 2003-06-04
KR100901102B1 (ko) 2009-06-08
CN1655776A (zh) 2005-08-17
BRPI0114042B1 (pt) 2016-11-08
RU2694361C2 (ru) 2019-07-12
US8114890B1 (en) 2012-02-14
BRPI0114042B8 (pt) 2021-05-25
KR100918223B1 (ko) 2009-09-21
US6414016B1 (en) 2002-07-02
AR100291A2 (es) 2016-09-28
RU2694361C9 (ru) 2019-12-25
DK1315485T3 (da) 2008-03-03
EP1315485B1 (en) 2007-11-21
HUP0302422A2 (hu) 2003-10-28
US20050222195A1 (en) 2005-10-06
NZ524401A (en) 2004-08-27
JP2009114217A (ja) 2009-05-28
PT1857105E (pt) 2010-10-08
DE60142810D1 (de) 2010-09-23
HUP0302422A3 (en) 2005-02-28
TWI305147B (en) 2009-01-11
EP1857105A2 (en) 2007-11-21
NO332701B1 (no) 2012-12-10
US6610732B2 (en) 2003-08-26
EP1857105B1 (en) 2010-08-11
IL154534A (en) 2010-04-29
CA2419741A1 (en) 2002-03-14
MXPA03001959A (es) 2003-06-24
DE60131547T2 (de) 2008-10-23
BR0114042A (pt) 2003-07-22
CN100335049C (zh) 2007-09-05
NL300757I2 (ru) 2015-12-29
JP2009286806A (ja) 2009-12-10
PT1315485E (pt) 2008-01-23
AR030609A1 (es) 2003-08-27
US20120022152A1 (en) 2012-01-26
NO20030996L (no) 2003-05-02
NO20030996D0 (no) 2003-03-04
WO2002020007A1 (en) 2002-03-14
DE60131547D1 (de) 2008-01-03
KR20080091278A (ko) 2008-10-09
ES2296786T3 (es) 2008-05-01
AU8261501A (en) 2002-03-22
CA2419741C (en) 2010-11-30
JP4684334B2 (ja) 2011-05-18
EP1857105A3 (en) 2008-03-05
ES2347697T3 (es) 2010-11-03
US20030216465A1 (en) 2003-11-20
HU229319B1 (en) 2013-10-28
JP2004508327A (ja) 2004-03-18
CZ304740B6 (cs) 2014-09-17
IL154534A0 (en) 2003-09-17
US8748454B2 (en) 2014-06-10
US20030040528A1 (en) 2003-02-27
RU2694361C3 (ru) 2020-07-20
ATE476975T1 (de) 2010-08-15
US20140235665A1 (en) 2014-08-21
KR20030029919A (ko) 2003-04-16
DK1857105T3 (da) 2010-09-20

Similar Documents

Publication Publication Date Title
ZA200301673B (en) Cathartic composition.
EG24742A (en) Vaccine composition.
GB0026018D0 (en) New composition
ZA200301274B (en) Gasoline composition.
HUP0400589A3 (en) Colostrum-based composition
ZA200205528B (en) Glyburide composition.
SG99895A1 (en) Proanthocyanidin-containing composition
MXPA03004993A (es) Composiciones de policarbonato.
IL145793A0 (en) Odor-eliminating composition
GB0023891D0 (en) Composition
EP1270611A4 (en) COMPOSITION
ZA200105597B (en) Antibacterial composition.
GB0109427D0 (en) Arthropod-controlling composition
MXPA01000464A (es) Composicion.
AU2001287852A8 (en) Composition
GB0007762D0 (en) Composition
GB0025058D0 (en) Composition
GB0119165D0 (en) Composition
ZA200105855B (en) Chemical composition.
ZA200005574B (en) Insecticidal composition.
ZA200100367B (en) Composition comprising sulphamate compound.
GB0000845D0 (en) Composition
GB0020916D0 (en) Composition
GB0023067D0 (en) Composition
GB0023416D0 (en) Composition